Table 1 Demographic and clinical characteristics of the different cohorts.
From: Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
Group | Total | Female | Male | 60–69 | 70–79 | 80+ | General Jewish | Ultra-Orthodox Jewish | Arabs | |
|---|---|---|---|---|---|---|---|---|---|---|
2 Doses 4+ months N = 111,531 Person-days at risk = 3,858,236 | % person days at risk | 100% | 60.80% | 39.20% | 53.50% | 28.00% | 18.50% | 63.20% | 5.70% | 31.10% |
# severe Covid-19 (rate) | 469 (12.2) | 236 (10.1) | 233 (15.4) | 100 (4.8) | 142 (13.1) | 227 (31.9) | 281 (11.5) | 18 (8.2) | 170 (14.2) | |
3 Doses 0–1 months N = 31,955 Person-days at risk = 446,008 | % person days at risk | 100% | 59.80% | 40.20% | 47.20% | 30.00% | 22.80% | 77.80% | 5.10% | 17.10% |
# severe Covid-19 (rate) | 29 (6.5) | 12 (4.5) | 17 (9.5) | 5 (2.4) | 7 (5.2) | 17 (16.7) | 22 (6.3) | 2 (8.8) | 5 (6.5) | |
3 Doses 1–2 months N = 40,172 Person-days at risk = 524,213 | % person days at risk | 100% | 60.40% | 39.60% | 51.00% | 29.70% | 19.30% | 77.70% | 4.90% | 17.40% |
# severe Covid-19 (rate) | 18 (3.4) | 11 (3.5) | 7 (3.4) | 3 (1.1) | 5 (3.2) | 10 (9.9) | 12 (2.9) | 1 (3.9) | 5 (5.5) | |
3 Doses 2–3 months N = 43,689 Person-days at risk = 683,876 | % person days at risk | 100% | 61.70% | 38.30% | 51.70% | 29.10% | 19.20% | 76.90% | 4.60% | 18.50% |
# severe Covid-19 (rate) | 30 (4.4) | 16 (3.8) | 14 (5.3) | 4 (1.1) | 8 (4) | 18 (13.7) | 25 (4.8) | 1 (3.2) | 4 (3.2) | |
3 Doses 3–4 months N = 96,809 Person-days at risk = 2,286,002 | % person days at risk | 100% | 59.60% | 40.40% | 57.00% | 27.40% | 15.60% | 78.10% | 4.20% | 17.70% |
# severe Covid-19 (rate) | 104 (4.5) | 45 (3.3) | 59 (6.4) | 17 (1.3) | 29 (4.6) | 58 (16.3) | 76 (4.3) | 4 (4.2) | 24 (5.9) | |
3 Doses 4–5 months N = 253,259 Person-days at risk = 7,262,548 | % person days at risk | 100% | 57.00% | 43.00% | 56.40% | 28.80% | 14.80% | 81.60% | 4.40% | 13.90% |
# severe Covid-19 (rate) | 353 (4.9) | 155 (3.7) | 198 (6.3) | 62 (1.5) | 111 (5.3) | 180 (16.7) | 270 (4.6) | 19 (5.9) | 64 (6.3) | |
3 Doses 5–6 months N = 683,273 Person-days at risk = 13,018,739 | % person days at risk | 100% | 54.70% | 45.30% | 51.80% | 32.40% | 15.80% | 84.60% | 4.80% | 10.60% |
# severe Covid-19 (rate) | 561 (4.3) | 220 (3.1) | 341 (5.8) | 89 (1.3) | 171 (4.1) | 301 (14.7) | 458 (4.2) | 28 (4.5) | 75 (5.4) | |
3 Doses 6–7 months N = 521,400 Person-days at risk = 5,942,383 | % person days at risk | 100% | 53.60% | 46.40% | 49.40% | 34.40% | 16.20% | 85.60% | 5.00% | 9.50% |
# severe Covid-19 (rate) | 75 (1.3) | 21 (0.7) | 54 (2) | 13 (0.4) | 24 (1.2) | 38 (3.9) | 49 (1) | 4 (1.4) | 22 (3.9) | |
4 Doses 0–2 months N = 515,029 Person-days at risk = 20,924,765 | % person days at risk | 100% | 52.60% | 47.40% | 32.00% | 41.70% | 26.30% | 93.90% | 2.70% | 3.50% |
# severe Covid-19 (rate) | 280 (1.3) | 113 (1) | 167 (1.7) | 28 (0.4) | 83 (1) | 169 (3.1) | 252 (1.3) | 6 (1.1) | 22 (3) | |
